Loading clinical trials...
Loading clinical trials...
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with moderately to severely active Ulcerative Colitis (UC). After the completion of the 12-week induction...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT04844606 · Ulcerative Colitis, Ulcerative Colitis Chronic, and more
NCT07550673 · Acute Severe Ulcerative Colitis
NCT06372613 · Ulcerative Colitis in Histologic Remission
NCT07374471 · Ulcerative Colitis (UC)
NCT05739864 · Active Ulcerative Colitis
Prometheus Biosciences Selected Center
Mobile, Alabama
Prometheus Biosciences Selected Site
Phoenix, Arizona
Prometheus Biosciences Selected Site
Sun City, Arizona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions